Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

7542Background: Elderly patients (pts) with Hodgkin lymphoma (HL) have few treatment (tx) options and poor outcomes compared to younger pts. This phase 2, frontline, open-label trial studied brentu...